Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture

Table 2

History of cancer and CIPN (no. of patients or mean ± SD).

	EA	HB	VitB	Placebo
Breast cancer	6 (42.9%)	3 (23.1%)	4 (26.7%)	8 (47.1%)
Ovarian cancer	3 (21.4)	3 (23.1%)	4 (26.7%)	3 (17.6%)
Other	1 (7.1%)	2 (15.4%)	1 (6.7%)	4 (23.5%)
Lymphoma	4 (28.6%)	5 (38.5%)	6 (40.0%)	2 (11.8%)
Time from first diagnosis (months)	12.1±11.6	24.9±38.6	14.0±13.8	14.5±13.7
Secondary cancer	2 (14.3%)	3 (23.1%)	4 (26.7%)	4 (23.5%)
Chemotherapy
Vinca alkaloids	4 (28.6%)	5 (28.5%)	6 (40.0%)	3 (17.6%)
Platin derivatives alone	1 (7.1%)	2 (15.4%)	0 (0.0%)	3 (17.6%)
Taxanes alone	6 (42.9%)	3 (23.1%)	4 (26.7%)	8 (47.1%)
Platin derivatives and taxanes combined	3 (21.4%)	3 (23.1%)	5 (33.3%)	5 (29.4%)
Total no. of different cytostatics	2.1±1.4	1.5±0.9	1.7±1.0	2.0±0.8
No. of diff. neurotoxic cytostatics only	1.6±1.2	1.1±0.3	1.2±0.4	1.3±0.6
Time from last chemotherapy (weeks)	20.1±27.4	27.8±49.3	8.7±5.8	14.2±17.0
Cancer surgery	11 (78.6%)	6 (46.2%)	10 (66.7%)	15 (88.2%)
Radiotherapy	9 (64.3%)	8 (61.5%)	7 (46.7%)	13 (76.5%)
Duration of CIPN > 6 months	6 (42.9%)	5 (38.5%)	5 (33.5%)	4 (23.5%)
CIPN stable or worsened	9 (64.3%)	7 (53.8%)	9 (60.0%)	10 (58.8%)